Assessing IV fluids to prevent pancreatitis after ERCP
Association Between Peri-procedural Intravenous Hydration and Post- Endoscopic Retrograde Cholangiopancreatography Pancreatitis
University of Calgary · NCT05211206
This study is testing if giving patients the right amount of IV fluids before and after a procedure can help prevent pancreatitis after an ERCP.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 13000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Calgary (other) |
| Locations | 1 site (Calgary, Alberta) |
| Trial ID | NCT05211206 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between peri-procedural intravenous fluid administration and the risk of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. It aims to evaluate short-term aggressive hydration regimens that are practical for outpatient settings, focusing on fluid type, volume, and timing. By analyzing these factors, the study seeks to identify effective strategies to reduce the incidence of post-ERCP pancreatitis, which is a significant adverse event associated with the procedure.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 years or older who are referred for ERCP and can provide informed consent.
Not a fit: Patients with contraindications to ERCP or those unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved protocols for IV fluid administration that significantly reduce the risk of pancreatitis after ERCP, enhancing patient safety and outcomes.
How similar studies have performed: Previous studies have shown that aggressive hydration can reduce the risk of post-ERCP pancreatitis, but this study's specific approach to short-term hydration regimens is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject referred for ERCP, regardless of indication; * Subject age 18 years or older; * Subject able to give informed consent to involvement be included. Exclusion Criteria: * Subject has a standard contraindication to ERCP; * Subject or surrogate unable or unwilling to provide informed consent; * Subject age \< 18 years.
Where this trial is running
Calgary, Alberta
- Peter Lougheed Hospital — Calgary, Alberta, Canada (RECRUITING)
Study contacts
- Principal investigator: Nauzer Forbes, MD MSc — University of Calgary
- Study coordinator: Nauzer Forbes, MD MSc
- Email: nauzer.forbes@ucalgary.ca
- Phone: 403-592-5089
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: ERCP